The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction – baseline. failure.9 A trial of ivabradine involving patients well as for the fidelity of this report to the trial tricular systolic dysfunction (BEAUTIFUL). The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction.
|Published (Last):||16 June 2006|
|PDF File Size:||13.74 Mb|
|ePub File Size:||16.94 Mb|
|Price:||Free* [*Free Regsitration Required]|
Ivabradine crosses the cell membrane and interacts within the pore loop from the intracellular side. Ivabradine did not affect the primary composite endpoint hazard ratio 1. Adjust the dose as needed based on resting heart rate and tolerability.
F does not store recipient email addresses. This entry form currently does not support special characters. Pharmacologic action Ivabradine blocks the hyperpolarization-activated cyclic nucleotide-gated channel responsible for the cardiac pacemaker I f current, which regulates heart rate.
Over 6, patients were randomized and followed for about Mean heart rate at baseline was Certain parts of this website offer the opportunity for users to post triap, information ivabrafine material including without limitation academic papers and data ‘Material’ in areas of the website.
In a prespecified subgroup of patients with heart rate of 70 bpm or greater, ivabradine treatment did not affect the primary composite outcome hazard ratio 0.
By posting Material you grant to F an irrevocable non-exclusive royalty-free license to keep a copy of Material for a reasonable period and as necessary to enable it to comply with its legal obligations. The recommended starting dose of ivabradine is 5 mg by mouth twice daily with meals.
Recommend to your librarian. The primary outcome was time to first cardiovascular death, admission to the hospital for acute MI, and admission to the hospital for new onset or worsening heart failure. In the overall study population treatment with ivabradine did not result in a significant reduction of the primary composite end point Cardiovascular death, admission to hospital for acute MI and admission to hospital for heart failure.
Administration The recommended starting dose of ivabradine is 5 mg by mouth twice daily with meals. F reserves the right to monitor all Material and to remove any Material which it considers in its absolute discretion to be unlawful, inappropriate, offensive or otherwise in breach of these Terms and Conditions.
We analysed patients by intention to treat. Accordingly you may only post Material that you have the right to do so. F does not claim any ownership in the Material that you or any other user posts. Ivabradine specifically inhibits the I f current in the sinoatrial node to lower heart rate, without affecting other aspects of cardiac function. You are a close professional associate of any of the authors e. Between December,and December,we screened 12 patients at centres in 33 countries.
Median follow-up was 19 months IQR To reduce the burden of cardiovascular disease. Between December,and December,we screened 12 patients at centres in 33 countries. In a prespecified subgroup of patients with heart rate of 70 bpm or greater, ivabradine treatment did not affect the primary composite outcome hazard ratio 0.
Munich, Germany, 31 August, However, there was no statistically significant difference in the primary outcome of all-cause or cardiovascular mortality. Ivabradine reduced heart rate by 6 bpm SE 0.
There was a problem providing the content you requested
To date, there are no well-established, head-to-head studies comparing ivabradine with other rate-lowering medications used in heart failure, such as digoxin.
Consider beautifjl following examples, but note that this is not an exhaustive list: A summary of the content will be automatically included.
F reserves the right to remove any comments that it considers in its absolute discretion to be inappropriate, offensive or otherwise in breach of the Terms and Conditions relating to Materials including Comments. Ivabradine is beautifl in Europe for the symptomatic treatment of chronic stable angina in coronary artery disease CAD patients who are in normal sinus rhythm and have a resting heart rate of 70 bpm or greater.
ESC sub specialties communities. Its predominant effect is to reduce heart rate without affecting contractility. Provide sufficient details of any financial or non-financial competing interests beauriful enable users to assess whether your comments might lead a reasonable person to question your impartiality.
Did you know that your browser is out of date? What is ivabravine to note is that most of these patients were already receiving the guidelines-recommended cardiovascular therapy: You are an Editor for the journal in which the article is published. However, it did reduce secondary endpoints: However, beta blockers have undesirable adverse effects i.
BEAUTIFUL TRIAL –
The study is registered with ClinicalTrials. Digoxin may also be used in concomitant atrial fibrillation, whereas ivabradine cannot. Reduction in heart rate with ivabradine does not improve cardiac outcomes in all patients with stable coronary artery disease and left-ventricular systolic dysfunction, but could be used to reduce the incidence of coronary artery disease outcomes in a subgroup of patients who have heart rates of 70 bpm or greater. The inhibition slows down depolarization and reduces heart rate.
This study also confirms that ivabradine is safe and well tolerated and can be used with all routinely prescribed cardiovascular drugs. Register Already registered with FPrime?
These terms shall be governed by and construed in accordance with English Law. I am an author of this article.
I am a Faculty Member who recommended this article.